AR053235A1 - Derivados de tienopirimidinas para el tratamiento de enfermedades inflamatorias - Google Patents
Derivados de tienopirimidinas para el tratamiento de enfermedades inflamatoriasInfo
- Publication number
- AR053235A1 AR053235A1 ARP060101573A ARP060101573A AR053235A1 AR 053235 A1 AR053235 A1 AR 053235A1 AR P060101573 A ARP060101573 A AR P060101573A AR P060101573 A ARP060101573 A AR P060101573A AR 053235 A1 AR053235 A1 AR 053235A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkynyl
- alkenyl
- alkyl
- aryl
- ring
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 7
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 5
- 125000002619 bicyclic group Chemical group 0.000 abstract 4
- -1 NR3.8.1R3.8.1 Chemical group 0.000 abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D521/00—Heterocyclic compounds containing unspecified hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuesto de la formula (1) en los que: X es O, S, SO o SO2; R1 es H, alquilo C1-6-, alquenilo C2-6, alquinilo C2-6, arilo C6-10 o aril C6-10-alquileno C1-6, heteroarilo C5-10-alquileno C1-6; R2 es H o un radical eventualmente mono- polisustituido seleccionado del grupo compuesto por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-10, mono- o bicíclico eventualmente puenteado una o varias veces, arilo C6-10, un anillo C3-10 heterocíclico aromático o no aromático, un anillo bicíclico y un arilo C6-10 condensado con un heterociclo C3-10; o NR1R2 significan juntos un anillo heterocíclico que está eventualmente sustituido con uno o varios radicales seleccionados de alquilo C1-4, alquenilo C2-6, alquinilo C2-6, alcanol C1- 6 lineal o ramificado y oxo; R3 un radical mono- o polisustituido seleccionado del grupo compuesto por un anillo C6-10 heterocíclico, cicloalquilo C3-7, aril C6-10-alquileno C1-6, heteroaril C5-10-alquileno C1-6, un anillo bicíclico condensado que eventualmente puede contener 1-4 heteroátomos seleccionados, de modo independiente entre sí, de N, O, S; o R3 significa fenilo eventualmente sustituido; o R3 significa un grupo COR3.7, COCH2R3.8, CONHR3.8 o SO2R3.8; en donde R3.7 es H, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7 o un radical seleccionado del grupo compuesto por arilo C6-10, un anillo C3-10 heterocíclico y un anillo bicíclico que eventualmente está sustituido con uno o varios radicales seleccionados del grupo compuesto por alquilo C1-6, alquenilo C2-6, alquinilo C2-6, halogeno, NR3.8.1R3.8.1, arilo C6-10 y un anillo C3-10 heterocíclico; en donde R3.8.1 es H, alquilo C1-6, alquenilo C2-6 o alquinilo C2-6; R3.8.2 es H, alquilo C1-6, alquenilo C2-6 o alquinilo C2-6; R4 es H, alquilo C1-4, alquenilo C2-4,alquinilo C2-4 u oxo; R5 es H, alquilo C1-4, alquenilo C2-4, o alquinilo C2-4; R6 es H, alquilo C1-4, alquenilo C2-4, o alquinilo C2-4; R7 es H, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, arilo C6-10 u OH; R8 es H, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, arilo C6-10 u OH; o R7 y R8 forman juntos oxo, así como sus sales, diastereomeros, enantiomeros, racematos, hidratos o solvatos farmacologicamente tolerables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005019201A DE102005019201A1 (de) | 2006-04-19 | 2006-04-19 | Neue Verbindungen zur Behandlung von entzündlichen Erkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053235A1 true AR053235A1 (es) | 2007-04-25 |
Family
ID=36678631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101573A AR053235A1 (es) | 2006-04-19 | 2006-04-21 | Derivados de tienopirimidinas para el tratamiento de enfermedades inflamatorias |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US7511045B2 (es) |
| EP (2) | EP1874781B9 (es) |
| JP (1) | JP5021624B2 (es) |
| KR (1) | KR101335964B1 (es) |
| CN (1) | CN101163706A (es) |
| AR (1) | AR053235A1 (es) |
| AT (1) | ATE434620T1 (es) |
| AU (1) | AU2006237354B2 (es) |
| BR (1) | BRPI0608387A2 (es) |
| CA (1) | CA2605161A1 (es) |
| CY (1) | CY1109348T1 (es) |
| DE (2) | DE502006004066D1 (es) |
| DK (1) | DK1874781T3 (es) |
| EA (1) | EA013108B1 (es) |
| ES (1) | ES2328400T3 (es) |
| HR (1) | HRP20090395T1 (es) |
| IL (1) | IL186749A (es) |
| MX (1) | MX2007012313A (es) |
| NO (1) | NO20074615L (es) |
| NZ (1) | NZ563488A (es) |
| PL (1) | PL1874781T3 (es) |
| PT (1) | PT1874781E (es) |
| RS (1) | RS51163B (es) |
| SI (1) | SI1874781T1 (es) |
| TW (1) | TWI380984B (es) |
| UA (1) | UA93872C2 (es) |
| WO (1) | WO2006111549A1 (es) |
| ZA (1) | ZA200707591B (es) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8114878B2 (en) * | 2006-04-19 | 2012-02-14 | Boehringer Ingelheim International Gmbh | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases |
| US8637519B2 (en) | 2007-10-19 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Heterocycle-substituted piperazino-dihydrothienopyrimidines |
| US8754073B2 (en) | 2007-10-19 | 2014-06-17 | Boehringer Ingelheim International Gmbh | Substituted piperazino-dihydrothienopyrimidines |
| US9090626B2 (en) | 2007-10-19 | 2015-07-28 | Boehringer Ingelheim International Gmbh | Piperazino-dihydrothienopyrimidine derivatives |
| US9150586B2 (en) | 2011-08-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| US10745411B2 (en) | 2011-08-24 | 2020-08-18 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006111549A1 (de) | 2005-04-21 | 2006-10-26 | Boehringer Ingelheim International Gmbh | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen |
| ES2462240T3 (es) * | 2006-02-28 | 2014-05-22 | Dart Neuroscience (Cayman) Ltd | Piperazinas terapéuticas como inhibidores de PDE4 |
| US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| PL2205608T3 (pl) * | 2007-10-18 | 2013-09-30 | Boehringer Ingelheim Int | Sposób otrzymywania dihydrotieno[3,2-d]pirymidyn i związków pośrednich stosowanych w tym sposobie |
| US20110028441A1 (en) * | 2007-10-19 | 2011-02-03 | Boehringer Ingelheim International Gmbh | Novel phenyl-substituted piperazino-dihydrothienopyrimidines |
| WO2009080533A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as orexin receptor antagonists |
| WO2009087127A1 (en) | 2008-01-11 | 2009-07-16 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| ES2428716T3 (es) | 2008-02-22 | 2013-11-11 | F. Hoffmann-La Roche Ag | Moduladores de beta-amiloide |
| CN102026984B (zh) * | 2008-05-13 | 2013-12-25 | 贝林格尔.英格海姆国际有限公司 | 二氢噻吩并[3,2-d]嘧啶二酚及类似嘧啶二酚的合成 |
| WO2010040661A1 (en) | 2008-10-09 | 2010-04-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| KR101293421B1 (ko) | 2008-11-10 | 2013-08-05 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 감마 분비효소 조절제 |
| US8637678B2 (en) * | 2008-12-24 | 2014-01-28 | Syngenta Limited | Methods for the preparation of aryl amides |
| EP2400961B1 (de) * | 2009-02-27 | 2017-11-22 | Boehringer Ingelheim International GmbH | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids |
| WO2010097334A1 (de) * | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids |
| CN102421767B (zh) * | 2009-03-10 | 2014-06-18 | 武田药品工业株式会社 | 苯并呋喃衍生物 |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US20140113877A1 (en) * | 2011-06-15 | 2014-04-24 | Takeda Gmbh | Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds |
| WO2013019966A1 (en) * | 2011-08-04 | 2013-02-07 | Allergan, Inc. | Aromatic bycyclic derivatives as cxcr4 receptor modulators |
| US9206195B2 (en) | 2011-08-09 | 2015-12-08 | Boehringer Ingelheim International Gmbh | Dihydrothienopyrimidines |
| GB201203266D0 (en) * | 2012-02-24 | 2012-04-11 | Randox Lab Ltd | Assay for the detection of the phenylpiperazine family |
| WO2014105958A2 (en) | 2012-12-26 | 2014-07-03 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
| WO2014117947A1 (en) * | 2013-02-04 | 2014-08-07 | Grünenthal GmbH | 4-amino substituted condensed pyrimidine compounds as pde4 inhibitors |
| WO2014124860A1 (en) | 2013-02-14 | 2014-08-21 | Boehringer Ingelheim International Gmbh | Specific pde4b-inhibitors for the treatment of diabetes mellitus |
| RU2668073C2 (ru) | 2013-03-14 | 2018-09-26 | Дарт Нейросайенс (Кайман) Лтд. | Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4 |
| CN104140426B (zh) * | 2013-05-07 | 2017-02-01 | 上海汇伦生命科技有限公司 | 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途 |
| CN103893183B (zh) * | 2014-03-12 | 2016-02-10 | 中山大学 | 1-（2-氯苯基）-4-{噻吩并[3,2-d]嘧啶-4-基}哌嗪化合物在制备抗HIV-1病毒药物中应用 |
| CA2969839A1 (en) * | 2014-12-05 | 2016-06-09 | Subramaniam Ananthan | Heterocyclic compounds as biogenic amine transport modulators |
| CN111587112B (zh) * | 2017-09-01 | 2023-10-10 | 卡德门企业有限公司 | Rho相关含卷曲螺旋蛋白激酶的抑制剂 |
| CN111108109A (zh) | 2017-09-20 | 2020-05-05 | 利奥制药有限公司 | 取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途 |
| EP3700529B1 (en) | 2017-10-23 | 2025-07-09 | Boehringer Ingelheim International GmbH | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) |
| EP3724196B9 (en) | 2017-12-15 | 2023-03-22 | UNION therapeutics A/S | Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors |
| ES2968822T3 (es) | 2017-12-15 | 2024-05-14 | Union Therapeutics As | Azetidina dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa |
| ES2968824T3 (es) | 2017-12-15 | 2024-05-14 | Union Therapeutics As | Tetrahidropirano dihidrotienopirimidinas sustituidas y su uso como inhibidores de la fosfodiesterasa |
| CN111285882B (zh) * | 2018-12-07 | 2022-12-02 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物、包含其的药物组合物及其制备方法和用途 |
| CN113248518B (zh) * | 2021-06-21 | 2022-03-25 | 山东大学 | 嘧啶哌嗪类衍生物及其制备方法与应用 |
| CA3234847A1 (en) | 2021-12-09 | 2023-06-15 | Boehringer Ingelheim International Gmbh | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases |
| US20230190754A1 (en) | 2021-12-09 | 2023-06-22 | Boehringer Ingelheim International Gmbh | Therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases |
| KR20250046278A (ko) * | 2022-08-09 | 2025-04-02 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | Pde4b 억제제 및 이의 용도 |
| CN119947728A (zh) | 2022-09-28 | 2025-05-06 | 勃林格殷格翰国际有限公司 | 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途 |
| WO2024067660A1 (zh) | 2022-09-29 | 2024-04-04 | 苏州爱科百发生物医药技术有限公司 | 氮杂稠环类化合物、其制备方法及其在医药上的应用 |
| CN115887463A (zh) * | 2022-12-27 | 2023-04-04 | 瑞石生物医药有限公司 | 一种含环酰胺化合物的药物组合物 |
| EP4678644A1 (en) | 2023-04-13 | 2026-01-14 | Shanghai Yidi Biotechnology Co., Ltd. | Substituted dihydrothienopyrimidine compound, preparation method therefor, and use thereof |
| CN116925099B (zh) * | 2023-07-21 | 2025-06-03 | 厦门大学 | 手性二氢噻吩并嘧啶亚砜的制备方法及其应用与其2、4位取代化合物 |
| WO2025067168A1 (zh) * | 2023-09-25 | 2025-04-03 | 苏州爱科百发生物医药技术有限公司 | 氮杂稠环类化合物及其制备方法和用途 |
| CN120398908A (zh) * | 2024-02-01 | 2025-08-01 | 艾派克斯生物科技有限公司 | Pde4b抑制剂及其药物组合物和用途 |
| WO2025162289A2 (zh) * | 2024-02-04 | 2025-08-07 | 西藏海思科制药有限公司 | 一种pde4b抑制剂的晶型及其在医药上的用途 |
| WO2025162431A1 (zh) * | 2024-02-04 | 2025-08-07 | 西藏海思科制药有限公司 | 一种pde4b抑制剂化合物的口服药物组合物及其制备方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470336A1 (de) | 1962-07-04 | 1969-03-20 | Thomae Gmbh Dr K | Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung |
| NL124131C (es) * | 1963-06-17 | |||
| DE1470356A1 (de) * | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| NL123139C (es) | 1965-03-31 | |||
| BE754606A (fr) * | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
| DE1940572A1 (de) * | 1969-08-08 | 1971-02-11 | Thomae Gmbh Dr K | Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| DE2032687A1 (en) * | 1970-07-02 | 1972-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa |
| US3763156A (en) * | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
| FR2082496A5 (es) | 1970-03-18 | 1971-12-10 | Westinghouse Freins & Signaux | |
| RO62428A (fr) * | 1971-05-04 | 1978-01-15 | Thomae Gmbh Dr K | Procede pour la preparation des thyeno-(3,2-d)-pyrimidines |
| DE2121950A1 (en) * | 1971-05-04 | 1972-11-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity |
| DE2750288A1 (de) * | 1977-11-10 | 1979-05-17 | Thomae Gmbh Dr K | Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| US4256737A (en) | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
| US4265738A (en) * | 1979-10-25 | 1981-05-05 | Goncharov Evgeny S | Cleaning and/or grading machine for free-flowing materials |
| US5187168A (en) * | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
| JPH07330777A (ja) * | 1994-06-08 | 1995-12-19 | Taisho Pharmaceut Co Ltd | チエノ［３，２−ｄ］ピリミジン−４−オン誘導体 |
| US6339089B2 (en) * | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
| IL155335A0 (en) | 2000-10-12 | 2003-11-23 | Boehringer Ingelheim Pharma | Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament |
| DE10064994A1 (de) * | 2000-12-23 | 2002-07-04 | Merck Patent Gmbh | Sulfamidothienopyrimidine |
| KR100971616B1 (ko) | 2001-06-22 | 2010-07-22 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 결정질 항콜린제, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
| US6587548B2 (en) | 2001-07-17 | 2003-07-01 | Hewlett-Packard Development Co., L.P. | Method and system of using a single telephone number for multiple services |
| WO2003055890A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| EP1465900B1 (en) * | 2002-01-10 | 2008-05-14 | Bayer HealthCare AG | Rho-kinase inhibitors |
| JP4015176B2 (ja) * | 2003-04-29 | 2007-11-28 | ファイザー・インク | 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類 |
| MY141220A (en) * | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| WO2005082865A1 (ja) * | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| WO2006111549A1 (de) | 2005-04-21 | 2006-10-26 | Boehringer Ingelheim International Gmbh | Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen |
-
2006
- 2006-04-19 WO PCT/EP2006/061680 patent/WO2006111549A1/de not_active Ceased
- 2006-04-19 BR BRPI0608387-0A patent/BRPI0608387A2/pt not_active IP Right Cessation
- 2006-04-19 PL PL06743350T patent/PL1874781T3/pl unknown
- 2006-04-19 EP EP06743350A patent/EP1874781B9/de active Active
- 2006-04-19 EP EP09152706A patent/EP2060575A1/de not_active Withdrawn
- 2006-04-19 SI SI200630405T patent/SI1874781T1/sl unknown
- 2006-04-19 CN CNA2006800134419A patent/CN101163706A/zh active Pending
- 2006-04-19 KR KR1020077027125A patent/KR101335964B1/ko not_active Expired - Fee Related
- 2006-04-19 EA EA200702200A patent/EA013108B1/ru not_active IP Right Cessation
- 2006-04-19 CA CA002605161A patent/CA2605161A1/en not_active Abandoned
- 2006-04-19 RS RSP-2009/0333A patent/RS51163B/sr unknown
- 2006-04-19 AU AU2006237354A patent/AU2006237354B2/en not_active Ceased
- 2006-04-19 JP JP2008507076A patent/JP5021624B2/ja active Active
- 2006-04-19 HR HR20090395T patent/HRP20090395T1/hr unknown
- 2006-04-19 ES ES06743350T patent/ES2328400T3/es active Active
- 2006-04-19 UA UAA200712658A patent/UA93872C2/ru unknown
- 2006-04-19 MX MX2007012313A patent/MX2007012313A/es active IP Right Grant
- 2006-04-19 AT AT06743350T patent/ATE434620T1/de active
- 2006-04-19 DK DK06743350T patent/DK1874781T3/da active
- 2006-04-19 DE DE502006004066T patent/DE502006004066D1/de active Active
- 2006-04-19 DE DE102005019201A patent/DE102005019201A1/de not_active Withdrawn
- 2006-04-19 NZ NZ563488A patent/NZ563488A/en not_active IP Right Cessation
- 2006-04-19 PT PT06743350T patent/PT1874781E/pt unknown
- 2006-04-20 TW TW095114162A patent/TWI380984B/zh not_active IP Right Cessation
- 2006-04-20 US US11/408,122 patent/US7511045B2/en active Active
- 2006-04-21 AR ARP060101573A patent/AR053235A1/es not_active Application Discontinuation
-
2007
- 2007-09-04 ZA ZA200707591A patent/ZA200707591B/xx unknown
- 2007-09-12 NO NO20074615A patent/NO20074615L/no not_active Application Discontinuation
- 2007-10-18 IL IL186749A patent/IL186749A/en not_active IP Right Cessation
-
2009
- 2009-02-19 US US12/388,835 patent/US7723341B2/en active Active
- 2009-09-10 CY CY20091100939T patent/CY1109348T1/el unknown
-
2010
- 2010-04-02 US US12/753,477 patent/US8354531B2/en active Active
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8114878B2 (en) * | 2006-04-19 | 2012-02-14 | Boehringer Ingelheim International Gmbh | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases |
| US8604039B2 (en) | 2006-04-19 | 2013-12-10 | Boehringer Ingelheim International Gmbh | Dihydrothienopyrimidines for the treatment of inflammatory diseases |
| US8822474B2 (en) | 2006-04-19 | 2014-09-02 | Boehringer Ingelheim International Gmbh | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases |
| US8637519B2 (en) | 2007-10-19 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Heterocycle-substituted piperazino-dihydrothienopyrimidines |
| US8754073B2 (en) | 2007-10-19 | 2014-06-17 | Boehringer Ingelheim International Gmbh | Substituted piperazino-dihydrothienopyrimidines |
| US9090626B2 (en) | 2007-10-19 | 2015-07-28 | Boehringer Ingelheim International Gmbh | Piperazino-dihydrothienopyrimidine derivatives |
| US9115142B2 (en) | 2007-10-19 | 2015-08-25 | Boehringer Ingelheim International Gmbh | Heterocycle-substituted piperazino-dihydrothienopyrimidines |
| US9150586B2 (en) | 2011-08-24 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| US10745411B2 (en) | 2011-08-24 | 2020-08-18 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053235A1 (es) | Derivados de tienopirimidinas para el tratamiento de enfermedades inflamatorias | |
| AR082112A1 (es) | Derivados de imidazopiridina, su procedimiento de preparacion y su aplicacion en terapeutica | |
| AR072657A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| AR070535A1 (es) | Compuestos inhibidores de raf y metodos para usarlos | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR036586A1 (es) | Nuevas dihidro-pteridinonas, procedimientos para su preparacion, su utilizacion como medicamentos y las formulaciones farmaceuticas que las contienen | |
| AR068075A1 (es) | Compuestos de piperazina con accion herbicida. proceso de preparacion | |
| AR082768A1 (es) | Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| AR072016A1 (es) | Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato | |
| CO6541645A2 (es) | Compuestos de indol y su uso farmaceutico | |
| CO6220934A2 (es) | Derivados de imidazolidinacaboxamida como inhibidores de lipasas y foffolipasas | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| PE20200388A1 (es) | Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock | |
| AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
| AR060516A1 (es) | Dihidrotienopirimidinas utilizables en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de pde4 y composiciones farmaceuticas que las contienen. | |
| AR076236A1 (es) | Compuestos organicos y sus usos | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CO6270309A2 (es) | Inhibidores tetrahidropiranocromeno de gamma secretasa | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| AR077510A1 (es) | Derivados de dihidroindolonas, su procedimiento de preparacion y las com-posiciones farmaceuticas que los contienen | |
| ECSP099216A (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR070264A1 (es) | Derivados de oxazepinopirimidona heteroarilamida sustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |